Clinicopathological significance of aberrant methylation of RARβ2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer
- 1 December 2004
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 46 (3) , 305-312
- https://doi.org/10.1016/j.lungcan.2004.05.003
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology (14570403-00)
This publication has 23 references indexed in Scilit:
- Hypermethylation ofFHITas a prognostic marker in nonsmall cell lung carcinomaCancer, 2004
- Carcinogen exposure differentially modulates RAR- promoter hypermethylation, an early and frequent event in mouse lung carcinogenesisCarcinogenesis: Integrative Cancer Research, 2003
- Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancerInternational Journal of Cancer, 2002
- Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung CarcinomasJNCI Journal of the National Cancer Institute, 2000
- RARβ2 specificity in mediating RA inhibition of growth of lung cancer-derived cellsLung Cancer, 2000
- How many tumor suppressor genes are involved in human lung carcinogenesis?Carcinogenesis: Integrative Cancer Research, 1999
- Expression of retinoic acid receptor genes in fetal and newborn rat lungPediatric Pulmonology, 1994
- Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.Proceedings of the National Academy of Sciences, 1987
- Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancerNature, 1987
- Loss of heterozygosity of chromosome 3p markers in small-cell lung cancerNature, 1987